Uncategorized
Visual acuity gains greater with intravitreal aflibercept than laser for macular edema due to BRVO
NEW ORLEANS — At 24 weeks, more patients in the intravitreal aflibercept arm of the VIBRANT study gained at least 15 letters of visual acuity than patients receiving laser to treat macular edema secondary to branch retinal vein occlusion, according to a presenter here. More than 90% of patients in both groups completed the primary outcome visit at week 24, with 53% of patients in the Eylea (aflibercept, Regeneron) group and 27% of patients in the laser group gaining 15 letters or more of visual acuity, W. Lloyd Clark, MD, (Read more...)